#obesity causes a lot of diseases including #arthritis. How? ⬆️ IL-6 ⬆️ leptin ⬆️ TNF-a @RheumNow #ACR24 @rheumarhyme https://t.co/qeqTZUOEZy

The Plants for Joints RA continuation made it to #ACR24! whole-food plant-based diet, exercise, sleep/stress Rx (added on to usual RA care i.e. DMARDs) Gains made during program were sustained, can't undersell lifestyle as part of the overall picture! #ACR24 ABST0530 @RheumNow https://t.co/XSLIwYitpH https://t.co/RfiTX8Z6ff

The TAPIR Trial on GPA shows higher (15.5%) relapse in the 0 mg prednisone arm vs. 4.2% in the 5 mg arm (OR 4.22), but does not impact PROs. Key finding: benefit of 5 mg/day seen only in non-rituximab regimens (20% vs. 2.6%, OR 9.50). Abstr#0774 Plenary 1 @RheumNow #ACR24… https://t.co/5DjW5Zwh0J https://t.co/UnsVPzJfs6

Want to lose weight naturally? Eat your veggies and protein first, and the carbs last— this reduces the post-prandial glucose, insulin and raises GLP-1 - Dr Aronne #ACR24 @RheumNow https://t.co/cRVRzRTljT

Dactylitis management in PsA: Acute: pain and swelling Chronic: painless swelling Broad ddx No role for LEF or SSZ #ReviewCourse #ACR24 @RheumNow https://t.co/KZXv1UvhXn

SELECT-GCA: Upa in GCA Merkel Upa 15 mg v 7.5 v PBO w slower GC taper 70% new onset, 30% relapse. Few prev on IL6 Primary endpt: sustained remission at w52- UPA 15 mg beats PBO (p=0.0019) 34% relapse in UPA vs 60% PBO Less steroids, longer time to flare @RheumNow #ACR24 #ACRBest https://t.co/1OV2889Ny0

Great summary of treatment choices in PsA: 1. Identify domain involved 2. Identify comorbidities/pt preferences 3. Still unmet needs for ttx in inflammatory eye disease #ACR24 @rheumnow https://t.co/1WMnkDYvip

Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/fr75XK21L1 https://t.co/Hhax7po7vV

What agent to pick after a TNFi has failed: another TNFi or a non-TNFi? Would a TNFi drug conc help (i.e. if low, increased clearance due to secondary failure)? In this RCT @maartenskliniek, this TDM approach was no better than random selection. Argh #ACR24 ABST0533 @RheumNow https://t.co/3h8o4ARZG3

Seronegative RA: sometimes there's an assumption that they'll eventually get a 'real' diagnosis at @MayoClinic, 85% of patients diagnosed with seronegative RA kept their diagnosis at 10 years. Usually, seroneg RA means seroneg RA! #ACR24 @MyasoedovaElena ABST0458 @RheumNow https://t.co/hErZVfs08k

❓What factors influence patient participation in rheumatology #ClinicalTrials? 📌 Come to poster 0366 to find out! 👨🏻‍⚕️ @KKouranloo & @chriswincup report results from a UK study, showing marked differences by ethnicity & RMD @RheumNow Ab0366 #ACR24 https://t.co/kAqGJmNiPt

Real-world data from @k_lauper's Jak-pot study (>9000 RA pt) on how quickly b/tsDMARDs work: JAKi, TNFi quicker than tocilizumab, abatacept Even though they all get to a similar place eventually, some get there quicker (but worth any safety tradeoffs?) #ACR24 ABST0501 @RheumNow https://t.co/YVpTBMe3gi